PhRMA joins SMARxT drug disposal cause

SF 383 prohibits PBMs from limiting patient choice of pharmacy, unfairly excluding pharmacies from networks, and forces them to reimburse pharmacies no less than what they pay affiliated pharmacies for the same drug.

Dae Lee, PharmD, Esq, CPBS and Lucas Morgan, Esq, discuss PBM and board of pharmacy enforcement actions, trends in PBM audits, and more.

Fitusiran (Qfitlia) is approved for patients 12 years and older with or without factor VIII or IX inhibitors.

As artificial intelligence evolves from a novel technology to commonplace in health care, the pharmacy industry is adapting to its challenges and opportunities.

US Senators on both sides of the aisle came together to announce the Protecting Pharmacies in Medicaid Act.

A conversation with Chelsee Jensen, PharmD, BCPS, director of formulary management at the Mayo Clinic.